XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3Close
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Net sales $ 4,209 $ 3,527 $ 12,186 $ 10,515
Cost of products sold 1,312 1,101 3,791 3,198
Gross profit 2,897 2,426 8,395 7,317 Close
Operating expenses:        
Selling, general and administrative expenses 1,562 1,242 4,372 3,811
Research and development expenses 407 356 1,156 1,051
Royalty expense 5 11 24 35
Amortization expense 205 208 631 620
Intangible asset impairment charges 0 1 276 58
Contingent consideration net expense (benefit) (23) 12 (4) 43
Restructuring net charges (credits) 8 15 12 51
Litigation-related net charges (credits) 0 (111) 0 (111)
Operating expenses 2,164 1,733 6,467 5,558 Close
Operating income (loss) 733 693 1,928 1,759 Close
Other income (expense):         Close
Interest expense (79) (66) (225) (200) Close
Other, net 14 (18) (7) (78) Close
Total Other Income Expenses -65.0 -84.0 -232.0 -278.0 0 Close
Income (loss) before income taxes 669 610 1,697 1,480 CloseClose
Income tax expense (benefit) 200 105 413 392 Close
Net income (loss) 468 504 1,284 1,088 Close
Preferred stock dividends 0 0 0 (23)
Net income (loss) attributable to noncontrolling interests 0 0 (4) 0
Net income (loss) attributable to Boston Scientific common stockholders $ 469 $ 505 $ 1,288 $ 1,065
Net income (loss) per common share — basic $ 0.32 $ 0.34 $ 0.88 $ 0.74
Net income (loss) per common share — diluted $ 0.32 $ 0.34 $ 0.87 $ 0.73
Weighted-average shares outstanding        
Basic 1,472.7 1,464.5 1,470.6 1,448.8
Diluted 1,487.4 1,475.0 1,484.5 1,459.1